IN BRIEF: Faron Pharma hails updated results from Matins study

Faron Pharmaceuticals Oy - Finland-based biopharmaceutical company with a pipeline focusing on ...

Alliance News 17 September, 2021 | 4:52PM
Email Form Facebook Twitter LinkedIn RSS

Faron Pharmaceuticals Oy - Finland-based biopharmaceutical company with a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy - Says updated results from the phase 1, 2, Matins study of its cancer immunotherapy drug candidate Bexmarilimab, strengthened its belief that it "can increase survival in patients with a variety of late-stage solid tumours."

Says updated results from the Matins study include patients from part one and part two of the trial. Current estimate for median progression free survival for all these patients was 59 days. Estimated median overall survival for all patients was 151 days.

Chief Executive Officer Markku Jalkanen says: "We look forward to discussing these results with the FDA and finalizing plans for the Part III expansion cohorts, which we hope to convert to pivotal stage development for a regulatory submission. Additionally, all biomarker data are currently being analyzed for potential patient selection purposes and we simultaneously continue to advance our plans to investigate bexmarilimab in additional clinical settings, including neoadjuvant therapy, in combination with checkpoint inhibitors and as a treatment for hematological malignancies."

Current stock price: 450.00 pence, up 9.1% on Friday

Year-to-date change: up 73%

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Faron Pharmaceuticals Oy 127.50 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures